...

 
Cannvas.Me
Sign Up For Free
  • Post Time Posted June 18, 2018

In a new interview with CNBC, Canopy Growth Corp. CEO Bruce Linton says that the focus of his company’s resources will be on producing and selling cannabis products, rather than simply cannabis as a “primary ingredient”.


Linton stated that the over-supply of dried flower in Canada by 2020 will mean that his company will need to shift to a more diverse product range. Among them, he touts beverages and sleeping aids as the ones he is most optimistic about.


Corona-producer Constellation Brands purchased a 10 percent stake in Canopy in late 2017, and with the FDA recently approving a cannabis-based epilepsy treatment drug, he believes that Canopy can develop a sleep aid that can be a “disruptor to Ambien”.


For the full interview, follow the link below.

https://www.cnbc.com/2018/06/28/from-sleep-aids-to-beverages-the-future-of-cannabis-is-in-products-c.html


This article is now marked as read.

Was this article helpful?

Review this article to help us continue creating and sharing relevant content.

Please note it may take up to two business days for reviews to be validated and published.

Reviews

Review this article to help us continue creating and sharing relevant content.

Write Review

Would you like to
make this review public?

Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.
Close